SCHEMBL7180409

SCHEMBL7180409

CCOc1cc(OCC)c(PC(=O)c2c(Cl)cccc2Cl)c(OCC)c1.[LiH]

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.47
KDM4E B2RXH2 1/20 0.40
RORC P51449 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189482 0.94 SMN1; SMN2 (0.45) ELANEKDM4ETAS1R3TAS1R1SMN1; SMN2
SCHEMBL7181471 0.94 ELANE (0.43) ELANEKDM4ERORCSMN1; SMN2NPC1
SCHEMBL7186608 0.87 ELANE (0.42) ELANERORCNPC1RAB9AALDH1A1
SCHEMBL7185529 0.86 KDM4E (0.40) ELANEKDM4ESMN1; SMN2ALDH1A1NFKB1
SCHEMBL7190024 0.86 L3MBTL1 (0.43) ELANEKDM4EPOLBALDH1A1L3MBTL1
SCHEMBL7187854 0.86 FAAH (0.41) ELANERORCSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL7179890 0.85 SMN1; SMN2 (0.49) KDM4ESMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL7182812 0.85 THRB (0.44)
SCHEMBL7178061 0.84 KDM4E (0.45) ELANEKDM4ERORCTAS1R3TAS1R1
SCHEMBL7182256 0.84 THRB (0.46) LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ELANE 4357/4885KDM4E 3226/4885RORC 1336/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ELANE 4460/4885KDM4E 2651/4885RORC 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.